Cancer Research UK
Funding Body Agreement
Cancer Research UK grantees are required to submit an electronic copy of the final manuscripts of their research papers, submitted to journals after June 1, 2007, to PubMed Central (PMC) or UK PubMed Central (UKPMC). Cancer Research UK requires that the author’s work be made available to the public, via PMC and PMC mirror sites, no later than six months after final publication (see Policy on Open Access and PubMed Central).
Elsevier’s policy will allow authors who publish in Elsevier journals to comply with these requirements. This policy is intended to support the needs of Elsevier authors, editors and society publishing partners, and to protect the quality and integrity of the peer-review process.
Cancer Research UK-funded authors publishing in Elsevier journals can comply with the Cancer Research UK policy by paying a fee to the journal to help offset the cost of peer review and other publishing costs. For information about open access publication fees, please refer to the individual journal homepage or guide for authors.
Upon final publication, Elsevier will send to PMC the final document used to generate the published journal article that appears on ScienceDirect. This document reflects all author-agreed changes that arise from the peer-review, copy-editing and proofing processes. Elsevier will authorize its public posting on PMC, and PMC mirror sites, immediately. PMC and PMC mirror sites will also link directly to the final published journal article, which will continue to reside only on Elsevier’s websites and which Elsevier will make freely available to both non-subscribers and subscribers. Subject to certain conditions, documents published under this sponsorship model may be redistributed and reused.
There is no change to Elsevier’s author posting policy that allows authors to post revised personal versions of manuscripts (those that reflect changes made in the peer review) on their own websites and the sites of their institutions, provided a link to the journal is included. Posting directly to PMC or other sites outside an author’s institution continues to be prohibited, as does any further republishing or redistribution of Elsevier copyright-protected content and society copyright-protected content published by Elsevier. This new policy enables Cancer Research UK-funded authors to comply with the Cancer Research UK policy without having to violate their publishing agreements with Elsevier.
This policy is consistent with Elsevier’s long-standing record of adapting to meet authors’ changing needs, preserving the quality and integrity of the peer-review process, and providing value throughout the publishing cycle. It is another example of Elsevier’s ongoing engagement with scientific and academic communities to explore ways to deliver demonstrable and sustainable benefits for the research communities we serve.